nature portfolio

Corresponding author(s):	Takashi Toyama
Last updated by author(s):	Jul 21, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics					
For all statistical a	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed	/a Confirmed				
☐ ☐ The exac	exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A statem	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The stati	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A descrip	A description of all covariates tested				
A descrip	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give P values as exact values whenever suitable.					
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software ar	nd code				
Policy information about <u>availability of computer code</u>					
Data collection	Data collection CFX Maestro (qPCR), ImageSaver6 (Western blottings), and fluoview (fluorescence images).				
Data analysis	Graphpad Prism and ImageJ were used.				
	ng custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and vencourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				
Data					
	about <u>availability of data</u>				
All manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets					
- A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to our policy					
- FOI CIINICAI DAT	asets or third party data, please ensure that the statement adheres to our <u>policy</u>				

The data supporting this manuscript are available from the corresponding author by reasonable request.

Research inv	olving hu	man participants, their data, or biological material	
Policy information and sexual orientat		vith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> thnicity and racism.	
Reporting on sex	and gender	No studies with human participants are included in the manuscript.	
Reporting on race other socially rele groupings		No studies with human participants are included in the manuscript.	
Population chara	cteristics	No studies with human participants are included in the manuscript.	
Recruitment		No studies with human participants are included in the manuscript.	
Ethics oversight		No studies with human participants are included in the manuscript.	
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.	
Field-specific reporting			
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences			
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life scier	nces stu	udy design	
All studies must disclose on these points even when the disclosure is negative.			
Sample size	No statistical method was used to determine sample size.		
Data exclusions	No data was excluded		
Replication	Biochemical experiments were examined at least three times independently, and their average or representative ones were shown in the manuscript		
Randomization	No randomization was performed in this study		
Blinding	No blinding was performed in this study		
Reporting for specific materials, systems and methods			
· ·		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & experimental systems Methods			
n/a Involved in the study n/a Involved in the study			
Antibodies ChIP-seq			
Eukaryotic cell lines Flow cytometry			
Palaeontology and archaeology MRI-based neuroimaging			
☐ X Animals and other organisms			

Antibodies

Antibodies used

Plants

Clinical data

Dual use research of concern

anti- β -actin A5441, clone AC-15, anti-GPx1 ab108427, anti-GPx4 ab125066, anti-HO-1 sc-390991, anti-LAMP2 sc-18822, anti-LC-3A/B 12741S, anti-LC-3A/s anti-LC

Validation

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.sigmaaldrich.com/specification-sheets/141/510/A5441-BULK_____SIGMA___.pdf
https://www.abcam.co.jp/products/primary-antibodies/glutathione-peroxidase-1-antibody-epr3312-ab108427.html
https://www.abcam.co.jp/products/primary-antibodies/glutathione-peroxidase-4-antibody-epncir144-ab125066.html
https://www.scbt.com/ja/p/heme-oxygenase-1-antibody-f-4
https://www.scbt.com/ja/p/lamp-2-antibody-h4b4
https://www.cellsignal.jp/products/primary-antibodies/lc3a-b-d3u4c-xp-rabbit-mab/12741
https://www.scbt.com/ja/p/nrf2-antibody-a-10
https://www.cellsignal.jp/products/primary-antibodies/sqstm1-p62-antibody/5114

Selenoprotein P antibodies were validated using serum of SeP KO mice in this study and previous report (Mita et al., 2017).

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

Cell line source(s) HepG2 (derived from human liver carcinoma, which obtained from JCRB cell bank)

Authentication No further authentication was performed for the cell line

Mycoplasma contamination Not tested for mycoplasma contamination

Commonly misidentified lines (See ICLAC register)

No commonly misidentified lines were used

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in</u> Research

Laboratory animals

male 6-week-old C57BL/6J mice (Claire Japan), Male 16-week-old KKAy mice (CLEA Japan, Kanagawa, Japan), and male 6-week-old Nrf2 (-/-) mice, Keap1flox/flox::Alb-Cre mice, and Selenoprotein P (-/-) mice were used in this study.

No wild animals are used in this study

In this study, experiments were conducted using only males, and differences between males and females were not taken into account.

Field-collected samples

No field-collected samples were used

The animal study was carried out in accordance with the rules and guidelines for the proper implementation of animal experiments at Tohoku University (Approval No. 2019-018-05)

Note that full information on the approval of the study protocol must also be provided in the manuscript.